CRISPR Therapeutics, Inc. remote jobs and company guide

CRISPR Therapeutics was founded in 2013 with a transformative vision: to harness the revolutionary CRISPR/Cas9 gene-editing technology to develop medicines capable of treating and potentially curing serious human diseases. The company's origins trace back to 2012, when Emmanuelle Charpentier, Ph.D. and Jennifer Doudna, Ph.D. authored the historic scientific paper on CRISPR/Cas9 as a gene-editing tool, work for which they later received the Nobel Prize in Chemistry in 2020.

From its early beginnings as a research-stage organization, CRISPR Therapeutics has evolved into an industry leader that achieved a historic milestone with the approval of CASGEVY™ (exagamglogene autotemcel), the world's first CRISPR-based gene-edited therapy. This treatment, developed in collaboration with Vertex Pharmaceuticals, is approved in several countries for eligible patients suffering from sickle cell disease or transfusion-dependent beta thalassemia. The company's mission centers on finding cures for people suffering from serious diseases through transformative gene-based medicines, and this patient-forward philosophy guides everything they do.

Today, CRISPR Therapeutics operates from its global headquarters in Zug, Switzerland, with its wholly-owned U.S. subsidiary and R&D operations based in Boston, Massachusetts, and San Francisco, California. The company has established strategic partnerships with leading biopharmaceutical companies and continues to expand its pipeline across hemoglobinopathies, oncology, regenerative medicine, cardiovascular disease, autoimmune conditions, and rare diseases. With state-of-the-art manufacturing facilities and a team of dedicated professionals, CRISPR Therapeutics remains at the forefront of gene editing innovation, developing proprietary platforms like SyNTase™ editing to enable precise, efficient, and scalable gene correction for the next generation of medicines.